The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
18 years of age or older
De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry
Able and willing to participate in baseline and follow up evaluations for the full length of the registry
Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
Long-standing persistent AF (AF greater than one year's duration)
Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry
In the opinion of the investigator, any known contraindication to an ablation procedure
Heart Rhythm Clinical and Research Solutions, LLC
Lead sponsor
Biosense Webster, Inc.
Collaborator